MAS-Seq Supports Isoform Research Using
Single-Cell RNA Sequencing from 10x Genomics
MENLO
PARK, Calif., Oct. 20,
2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a
leading developer of high-quality, highly accurate sequencing
solutions, today announced the launch of its Multiplexed Arrays
Sequencing (MAS-Seq) kit in partnership with the Broad Institute of
MIT and Harvard and 10x Genomics, Inc. The kit is a
first-of-its-kind kitted solution leveraging 10x Genomics' Single
Cell Gene Expression technology to enable cost-effective long-read
single-cell RNA sequencing for a more complete interrogation of the
transcriptome. Insights generated from single-cell RNA sequencing
experiments can power new disease discoveries and the
identification of therapeutic targets across many categories.
"We're thrilled to collaborate with these innovative
organizations and bring new capabilities to our customers, enabling
them to unlock new discoveries in their research," said
Christian Henry, President and Chief
Executive Officer of PacBio. "With this first-of-its-kind kit,
PacBio aims to empower customers' single-cell research in a way
that has not been possible before. The availability of MAS-Seq is a
significant milestone for PacBio."
MAS-Seq will help single-cell researchers better identify and
characterize novel isoforms, novel driver mutations, and cancer
fusion genes, which are particularly relevant in the fields of
cancer research and neurodegenerative diseases.
"Understanding cell heterogeneity at the isoform level is
critical for basic and disease research," said Jeff Eidel, Chief Commercial Officer at PacBio.
"Our customers understand the need for HiFi sequencing to obtain
full-length isoforms at single-cell resolution with accuracy. With
the MAS-Seq technology, we aim to bring the throughput increase
that enables customers to use HiFi for single-cell RNA sequencing
in a cost-effective manner."
Together with the kit, PacBio will also release new SMRTLink
software that supports single-cell transcriptome analysis, helping
researchers easily glean insights from their data.
"The single cell revolution has already led to groundbreaking
discoveries in biomedical research and has transformed our
understanding of disease and development, yet there are so many
more research questions and applications waiting to benefit from
the power of single cell analysis," said Edwin Hauw, Vice President of Marketing for 10x
Genomics. "We believe the ability to characterize single cells at
the transcript isoform-level will fuel discoveries of new
biomarkers that are important in both disease research and cellular
function, helping to unlock new biological insights and open up new
application areas. The combination of the MAS-Seq kit with our
industry-leading Chromium assays is yet another way 10x Genomics is
working to build and deliver the most comprehensive single cell
portfolio for researchers worldwide."
The MAS-Seq kit is the first in a series of products from PacBio
to be included in its partnership with 10x Genomics as part of
their Compatible Partner Program (CPP). The compatible partner
program includes products that have been verified with 10x Genomics
workflows.
"To date, we have had tremendous success using bulk Iso-Seq to
facilitate the discovery of novel gene and isoform-resolved
regulatory events pertaining to specific disease and developmental
states. Today, we are excited to apply MAS-Seq technology to
pioneer beyond tissue-specific associations and begin assigning
these transcriptional features to specific cell populations.
MAS-Seq data will ultimately better stratify disease-associated
biology and enable more robust biomarker discovery for future
functional validation from organism to tissue and now cell-specific
outcomes," said Robert P. Sebra,
Ph.D., Professor of Genetics and Genomic Sciences and Director of
the Center for Advanced Genomics Technology at the Icahn School of
Medicine at Mount Sinai.
PacBio is now accepting orders for the MAS-Seq kit which will
begin shipping in early November. PacBio will host a webinar on
November 16, 2022 that describes the
MAS-Seq library and bioinformatics workflow in detail and is open
for registration here.
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a
premier life science technology company that is designing,
developing and manufacturing advanced sequencing solutions to help
scientists and clinical researchers resolve genetically complex
problems. Our products and technology under development stem from
two highly differentiated core technologies focused on accuracy,
quality and completeness which include our existing HiFi long read
sequencing and our emerging SBB™ short read sequencing
technologies. Our products address solutions across a broad set of
research applications including human germline sequencing, plant
and animal sciences, infectious disease and microbiology, oncology,
and other emerging applications. For more information, please
visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use
in diagnostic procedures.
Forward-Looking Statements
This press release may contain "forward-looking statements" within
the meaning of Section 21E of the Securities Exchange Act of 1934,
as amended, and the U.S. Private Securities Litigation Reform Act
of 1995, including statements relating to future availability,
uses, accuracy, advantages, quality or performance of, or benefits
or expected benefits of using, PacBio products or technologies,
including in connection with the MAS-Seq kit, new software
supporting single-cell transcriptome analysis, and other future
events. Readers are cautioned not to place undue reliance on these
forward-looking statements and any such forward-looking statements
are qualified in their entirety by reference to the following
cautionary statements. All forward-looking statements speak only as
of the date of this press release and are based on current
expectations and involve a number of assumptions, risks and
uncertainties that could cause the actual results to differ
materially from such forward-looking statements. Readers are
strongly encouraged to read the full cautionary statements
contained in PacBio's filings with the Securities and Exchange
Commission, including the risks set forth in PacBio's Forms 8-K,
10-K, and 10-Q. PacBio disclaims any obligation to update or revise
any forward-looking statements.
Contacts
Investors:
Todd Friedman
650.521.8450
ir@pacb.com
Media:
Lizelda Lopez
pr@pacb.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pacbio-launches-single-cell-transcriptome-solution-ushering-in-a-new-era-of-rna-discovery-301654374.html
SOURCE Pacific Biosciences of California, Inc.